FAQs

What is the Global CEO Initiative?

The Global CEO Initiative on Alzheimer’s Disease (CEOi) is a public-private partnership initiated by leading global corporations and involving non-profit and governmental organizations to identify and advance high-priority activities necessary to prevent and treat Alzheimer's disease by 2025 and improve the quality of life for all affected by the disease.

What is the purpose of the CEOi?

The CEOi has been formed to provide business leadership to the fight against Alzheimer’s. We intend to lend our voice to the social, fiscal, and political developments on Alzheimer’s in order to “change the game” by adding private-sector partnership and leadership.

What specific goals does the CEO Initiative have?

The CEOi aims to spur much-needed innovations that will improve the diagnosis, prevention, treatment, and care of those affected by Alzheimer’s. The CEOi aims to reduce the time, costs, and regulatory risks in order to improve the productivity of R&D investments. The CEOi will accelerate solutions for preventing and treating Alzheimer’s, improve our abilities to identify and diagnose the disease, and facilitate the development of new models for care and care delivery.

What companies are members?

The CEOi is currently supported by ten formational members with the goal of continuing to grow in the months ahead. The members span multiple industries and include: AC Immune, Bank of America, Banner Health, Eli Lilly, GE Healthcare, Janssen Research and Development (a division of Johnson & Johnson), Merck, Nestle, Pfizer, and Sanofi.

Are companies from all industries eligible?

Yes. The CEOi recognizes that Alzheimer's impacts all of society regardless of industry categories. Stopping Alzheimer's by 2025 will require the energies of the private sector en masse, and the CEO Initiative welcomes members from all sectors and industries.

How does a company become a member?

The CEOi is largely a "sweat-equity" coalition driven by the energies of its members. As such, members must be committed to the mission, vision and goals of the Initiative and be willing to commit appropriate levels of resources – including CEO and C-Suite participation – to advance the initiative. Members are also expected to make a financial contribution to provide the resources necessary to manage the effort and to support the priorities of the working groups.

How can non-profit organizations participate?

Non-profit organizations have key roles to play. The CEO Initiative is working closely with a number of non-profit organizations to lead various working groups and execute priority projects. Non-profits with specific expertise and skills to offer in our priority areas are welcome to offer their support. Additionally, non-profit organizations have and can continue to join the initiative as full corporate members if interested. More information can be obtained by contacting the CEOi directly.

Who is organizing and leading the Initiative?

The USAgainstAlzheimer's Network – a 501(c)(3) organization connecting networks of organizations and individuals – has provided organizational and managerial support of the Initiative through its conceptualization, formation and launch.

Who leads the Initiative?

The CEOi operates by consensus with the working groups developing and discharging plans of action under the approval of the larger group. Bob Ingram, former CEO/Chairman of GlaxoWellcome who co-led the merger that formed GlaxoSmithKline and the founder of the CEO Roundtable on Cancer, is the honorary chairman of the Global CEO Initiative on Alzheimer's Disease.

Why is the CEOi needed with so many other efforts and coalitions already underway?

The CEOi recognizes that a tremendous amount of activity is already taking place in the Alzheimer's space. The CEOi intends to align and focus this activity directly on advancing the goals of the U.S. National Plan and of similar global plans to prevent and treat the disease by 2025. The CEOi recognizes that while much is happening, much more remains to be done and is striving to accelerate and strengthen high-priority activities underway and to identify and fill gaps that may exist.

How were the priorities selected? Are other topics under consideration?

The priorities were selected after careful deliberation of CEOi formational members in consultation with experts including governmental officials and non-profit entities. The priorities track along with those established by the U.S. National Plan to Address Alzheimer's Disease and are consistent with the goals and priorities established by similar international plans. In selecting the current priorities and areas of focus for the working groups, the CEOi did not rule out other topics; rather, the group opted to focus its energies on a focused series of areas and projects aligned with the initial priorities of the Federal government designed to achieve meaningful progress on the goals of the National Plan. As projects are advanced and the Initiative expanded, we look forward to pursuing additional priorities and projects.

How can I get more information?

For more information, please visit our website at www.ceoalzheimersinitiative.org.